{"The": [0, 138, 155, 209], "monoclonal-antibody": [1], "combination": [2], "AZD7442": [3, 45, 121, 175, 195, 201, 235, 274, 339], "is": [4], "composed": [5], "of": [6, 50, 64, 71, 85, 116, 120, 146, 153, 168, 174, 185, 194, 216, 222, 229, 239, 255, 268, 279, 304, 312, 321, 338, 345], "tixagevimab": [7, 110], "and": [8, 26, 33, 111, 125, 178, 190, 203, 237, 276, 326, 354], "cilgavimab,": [9], "two": [10, 327], "neutralizing": [11], "antibodies": [12], "against": [13, 77], "severe": [14, 322], "acute": [15], "respiratory": [16], "syndrome": [17], "coronavirus": [18, 78], "2": [19], "(SARS-CoV-2)": [20], "that": [21, 44], "have": [22, 27, 31], "an": [23, 47, 54, 68, 72, 82], "extended": [24, 48, 299], "half-life": [25, 49], "been": [28], "shown": [29], "to": [30, 75, 87, 99, 131, 296, 317], "prophylactic": [32], "therapeutic": [34], "effects": [35], "in": [36, 41, 95, 134, 199, 205, 233, 243, 261, 266, 272, 277, 283, 332], "animal": [37], "models.": [38], "Pharmacokinetic": [39], "data": [40], "humans": [42], "indicate": [43], "has": [46], "approximately": [51], "90": [52], "days.In": [53], "ongoing": [55], "phase": [56], "3": [57], "trial,": [58], "we": [59], "enrolled": [60], "adults": [61], "(\u226518": [62], "years": [63], "age)": [65], "who": [66], "had": [67, 219, 340], "increased": [69, 83], "risk": [70, 84, 288, 310], "inadequate": [73], "response": [74], "vaccination": [76], "disease": [79], "2019": [80], "(Covid-19),": [81], "exposure": [86], "SARS-CoV-2,": [88], "or": [89, 122, 176, 180, 196, 259, 323], "both.": [90], "Participants": [91], "were": [92, 127, 257], "randomly": [93], "assigned": [94], "a": [96, 101, 150, 302, 308], "2:1": [97], "ratio": [98], "receive": [100], "single": [102, 151, 336], "dose": [103, 152, 193, 337], "(two": [104], "consecutive": [105], "intramuscular": [106], "injections,": [107], "one": [108, 192, 251], "containing": [109, 114], "the": [112, 135, 144, 200, 206, 217, 234, 244, 273, 284, 333, 343, 355], "other": [113], "cilgavimab)": [115], "either": [117], "300": [118], "mg": [119], "saline": [123], "placebo,": [124], "they": [126], "followed": [128], "for": [129, 342], "up": [130], "183": [132], "days": [133], "primary": [136, 139, 156, 210], "analysis.": [137], "safety": [140, 349], "end": [141, 158], "point": [142, 159], "was": [143, 160, 212], "incidence": [145], "adverse": [147, 252], "events": [148], "after": [149, 172, 214], "AZD7442.": [154], "efficacy": [157, 341], "symptomatic": [161], "Covid-19": [162, 264, 325], "(SARS-CoV-2": [163], "infection": [164], "confirmed": [165], "by": [166, 352], "means": [167], "reverse-transcriptase-polymerase-chain-reaction": [169], "assay)": [170], "occurring": [171], "administration": [173], "placebo": [177, 197, 207, 245, 285, 334], "on": [179], "before": [181], "day": [182], "183.A": [183], "total": [184], "5197": [186], "participants": [187, 218, 231, 241, 270, 281], "underwent": [188], "randomization": [189], "received": [191], "(3460": [198], "group": [202, 236, 246, 275, 286], "1737": [204], "group).": [208], "analysis": [211], "conducted": [213], "30%": [215], "become": [220], "aware": [221], "their": [223], "randomized": [224], "assignment.": [225], "In": [226], "total,": [227], "1221": [228], "3461": [230], "(35.3%)": [232], "593": [238], "1736": [240], "(34.2%)": [242], "reported": [247], "having": [248], "at": [249, 301], "least": [250], "event,": [253], "most": [254], "which": [256], "mild": [258], "moderate": [260], "severity.": [262], "Symptomatic": [263], "occurred": [265], "8": [267], "3441": [269], "(0.2%)": [271], "17": [278], "1731": [280], "(1.0%)": [282], "(relative": [287], "reduction,": [289], "76.7%;": [290], "95%": [291], "confidence": [292], "interval": [293], "[CI],": [294], "46.0": [295], "90.0;": [297], "P<0.001);": [298], "follow-up": [300], "median": [303], "6": [305], "months": [306], "showed": [307], "relative": [309], "reduction": [311], "82.8%": [313], "(95%": [314], "CI,": [315], "65.8": [316], "91.4).": [318], "Five": [319], "cases": [320], "critical": [324], "Covid-19-related": [328], "deaths": [329], "occurred,": [330], "all": [331], "group.A": [335], "prevention": [344], "Covid-19,": [346], "without": [347], "evident": [348], "concerns.": [350], "(Funded": [351], "AstraZeneca": [353], "U.S.": [356], "government;": [357], "PROVENT": [358], "ClinicalTrials.gov": [359], "number,": [360], "NCT04625725.).": [361]}